- Home
- AEMD vs PFSA Comparison
AEMD vs PFSA Comparison
Compare AEMD & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | PFSA |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.7M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | AEMD | PFSA |
|---|---|---|
| Price | $2.13 | $0.50 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 62.4K | ★ 105.0K |
| Earning Date | 02-12-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.05 |
| 52 Week High | $5.89 | $4.22 |
Technical Indicators
Market Signals| Indicator | AEMD | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 35.55 |
| Support Level | $1.86 | $0.43 |
| Resistance Level | $2.79 | $0.66 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 70.43 | 16.97 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About PFSA Profusa Inc.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.